Morgan Stanley provided color on Bristol Myers Squibb BMY. In a research report published today, Morgan Stanley commented on the performance of the company's drug dapagliflozin.
In the report, Morgan Stanley states, “Dapagliflozin (SGLT2 for diabetes) showed
numerically higher bladder and breast cancer rates
in clinical trials, and the key question is what
regulatory authorities will think. Data presented at
ADA over the weekend revealed that there were nine
bladder cancers in 5,478 patients on dapagliflozin vs.
one bladder cancer in 3,156 patients in control groups
and nine breast cancers in 2,223 women on
dapagliflozin vs. one in 1,053 women in control groups.”
At the moment, Morgan Stanley has an Overweight rating placed on the company's stock. On Friday, BMY lost 1.36% of its value to finish the week at $28.93.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in